ArticleIndian journal of pharmacology2026
Pharmacovigilance of paracetamol-induced Stevens-Johnson Syndrome and toxic epidermal necrolysis in the Indian population.
Article in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsDespite decades of proven safety of paracetamol, serious and rare reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) often occur in the Indian population. The current study aimed to understand the safety profile of this relatively safer drug, paracetamol, with respect to rare and serious adverse events, SJS/TEN, based on data collected from the Indian population through the Pharmacovigilance Programme of India.
methodsThe collected, collated and analyzed all Individual Case Safety Reports with the use of paracetamol from the Indian population for the period January 1, 2010, to December 31, 2021, were reported to VigiBase and analyzed using the WHO database, VigiLyze.
resultsAnalysis of the reported data showed that 313 SJS/TEN adverse events were associated with the use of paracetamol. Disproportionality analysis of paracetamol-induced SJS/TEN reactions in the Indian population using the Proportional Reporting Ratio (PRR), reporting odds ratio, and the information component indicated higher risk of paracetamol in the Indian population.
conclusionsThe findings provide crucial insights into the extent of rare and infrequent SJS/TEN associated with the use of paracetamol in the Indian population. Owing to the seriousness of reaction and the widespread use of paracetamol for fever-like illness, the prescribing physicians, pharmacists, and other healthcare professionals should closely monitor patients administered paracetamol for this potential rare reaction, SJS/TEN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.